Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000930413-10-003839
Filing Date
2010-07-06
Accepted
2010-07-06 19:04:23
Documents
2
Period of Report
2010-07-01

Document Format Files

Seq Description Document Type Size
1 c62130_ex.html 4  
1 c62130_ex.xml 4 3531
2 c62130_ex24-1.htm EX-24.1 4698
  Complete submission text file 0000930413-10-003839.txt   10311
Mailing Address 685 ROUTE 202/206 ATT: GENERAL COUNSEL BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206 BRIDGEWATER NJ 08807 908 541 8671
ENZON PHARMACEUTICALS INC (Issuer) CIK: 0000727510 (see all company filings)

EIN.: 222372868 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O ENZON PHARMACEUTICALS, INC. 685 ROUTE 202/206 BRIDGEWATER NJ 08807
Business Address
Mulligan Richard (Reporting) CIK: 0001376247 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-12957 | Film No.: 10940642